Cargando…

Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity

Ferric citrate hydrate was recently approved in Japan as an oral phosphate binder to be taken with food for the control of hyperphosphatemia in patients with chronic kidney disease (CKD). The daily therapeutic dose is about 3 to 6 g, which comprises about 2 to 4 g of citrate. Oral citrate solubilize...

Descripción completa

Detalles Bibliográficos
Autor principal: Gupta, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210856/
https://www.ncbi.nlm.nih.gov/pubmed/25341358
http://dx.doi.org/10.3390/ph7100990

Ejemplares similares